Profile
MENS VRTX REGN VRNA ARGX ALNY
Company Name Jyong Biotech Ltd. Ordinary Shares Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $142.17M $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.03K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Fu-Feng Kuo Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
MENS VRTX REGN VRNA ARGX ALNY
Quant Rating Score 1 4 4 1 4 3
Quant Rating Strong Sell Buy Buy Strong Sell Buy Neutral
Trading
MENS VRTX REGN VRNA ARGX ALNY
Last Close $30.72 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $65.62 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $7.53 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -53.19 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 307.97 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
MENS VRTX REGN VRNA ARGX ALNY
1 Month Return -47.93 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return -25.98 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 0 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 0 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 0 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 0 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
MENS VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
MENS VRTX REGN VRNA ARGX ALNY
Asset Growth -22.82 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth 5.51 % 1.16 % - 26.81 %
Revenue Growth - 0.99 % - 22.97 %
Revenue 3 Year - 20.64 % -15.89 % 147.1 %
Revenue 5 Year - 73.64 % - 775.72 %
Revenue 10 Year - 285.02 % - 2487.4 %
EBIT Growth 45.54 % 9.09 % -131.37 % 24.59 %
Net Income Growth 31.39 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share 28.08 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share -48.32 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share -48.32 % 680.22 % -35.51 % 55.09 %
Operating Income Growth 26.49 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) -39.33 % - -143.33 % -107.98 %
Operating 3 Year CFG -82.66 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG -213.83 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG -213.83 % -100 % 40.15 % 97.08 %
EPS Growth 31.43 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth 31.43 % 8.19 % -208.93 % 38.07 %
Book Value Per Share -7.18 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share -56.57 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share -79.01 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share -79.01 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share - - - -
Debt Growth 8.65 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth -39.33 % - -144.48 % -201.54 %
Updated On 31 Dec 2024 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
MENS VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -3.33 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM 3.94 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -8.08 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 100 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 153.43 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -0 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM 19.33 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM - 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM - 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 23.7 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -0 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -167064.31 36.72 20 -995.27 127.92 195.85
Price To Operating Cash Flows Ratio TTM -157682.09 32.86 16.23 -126.33 144.41 162.25
Price Cash Flow Ratio TTM -157682.09 32.86 16.23 -126.33 144.41 162.25
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 23.61
AARD Aardvark Therapeutics, Inc. Common Stock 13.48
ABCL AbCellera Biologics Inc. 3.22
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.13
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.48
ABPWW 0.0155
ABSI Absci Corporation 2.76
ABUS Arbutus Biopharma Corporation 4.05
ABVC ABVC BioPharma, Inc. 1.73
ABVX Abivax SA American Depositary Shares 119.78
ACAD ACADIA Pharmaceuticals Inc. 23.22
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.25
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.33
ACIU AC Immune SA 3.11
ETFs With Exposure to MENS
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0 174.37
BIB ProShares Ultra Nasdaq Biotechnology 0.00731973 86.2807
IBBQ Invesco Nasdaq Biotechnology ETF 0.009667 29.677
2B70.DE iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 7.309
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 8.685
SBIO.MI Invesco NASDAQ Biotech UCITS ETF 0.0097 52.18
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF 0.01 8.651
SBIO.L Invesco NASDAQ Biotech UCITS ETF 0.0097 62.09
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 6.365
RFLR Innovator ETFs Trust 0.09 30
Unlock